Deep cuts at AstraZeneca, Sepracor

Share this article:
The cuts keep coming. AstraZeneca will make another 6,000 job cuts for a total of 15,000, or 23% of its global workforce of 65,000, by 2013, and Sepracor is slashing its sales force.

About half of the 15,000 AstraZeneca positions eliminated will come from sales, general and administrative functions, the company said, with another 41% coming from global supply chain operations and another 10% from R&D. All but 2,300 of those positions slated for elimination has been determined.

In November, AstraZeneca announced 1,400 job cuts as part of a realignment of its global manufacturing and supply chain operations. Those cuts were in addition to the 7,600 eliminations the company announced following its acquisition of MedImmune in 2007 – 1,800 of which came from a realignment of European sales forces. The company anticipates $2.5 billion in annual benefits from the reductions at a cost of $2.9 billion.

AstraZeneca reported fourth-quarter sales up 4%, but the gains were a wash, thanks to the negative impact of exchange rate movements. Full-year sales were up 3% worldwide. Sales in the US were up 3% for the fourth quarter and just 1% for the full year, as the impact of generic competition for Toprol-XL sank in.

Meanwhile, Sepracor announced that it would cut about 530 jobs, or 20% of its workforce, including 180 corporate positions and about 350 field-based positions, along with 410 contract sales reps. After restructuring, the company's sales force will total roughly 1,325 reps. The sales force cuts come with the roll out of a new commercial model featuring “geographically tailored field teams that have a regional profitability focus and sole territory product ownership,” and are expected to produce a reduction in operating expenses of about $210 million.

Also, Abbott is eliminating about 200 jobs – mostly sales and sales management, along with some marketing posts – after failing to gain approval for its 12-hour Vicodin CR formulation.

On Monday, Pfizer said it would cut between 18,000 and 19,000 jobs as part of its $68 billion acquisition of Wyeth.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...